Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Updated Guidance To Address New Humanitarian Device Exemption Provisions

This article was originally published in The Gray Sheet

Executive Summary

FDA plans on issuing updated guidance on humanitarian device exemptions "soon" to reflect provisions in the FDA Amendments Act of 2007, says Debra Lewis, associate director of the agency's Office of Orphan Products Development

You may also be interested in...



Guidance: How To Profit From Humanitarian-Use Devices In Pediatric Patients

1Draft guidance issued Aug. 5 clarifies FDA's new policy for allowing companies to profit from humanitarian-use devices in pediatric populations

Guidance: How To Profit From Humanitarian-Use Devices In Pediatric Patients

1Draft guidance issued Aug. 5 clarifies FDA's new policy for allowing companies to profit from humanitarian-use devices in pediatric populations

Pediatric Device Developers Counting On Easier Path To Market

Developing medical technologies exclusively for children has not typically been an easy or profitable path to tread

UsernamePublicRestriction

Register

PS100968

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel